Form DEFA14A BridgeBio Pharma, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Form DEFA14A BridgeBio Pharma, Inc.
April 28, 2026 2:00 PM EDT
Raymond James analyst Martin Auster reiterated an Outperform rating and $89.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "Today, Pfizer announced (here) that the company has entered into settlement agreements with several generic drug manufacturers over patent infringement lawsuits relating to Pfizers blockbuster ATTR-CM product, Vyndamax (tafamidis). Here, we summarize key takeaways and contextualize readthrough to BridgeBios lead ATTR-CM asset, Attruby. Vyndamax settlements and June 2031 LoE timeline roughly within Street expectations. Todays settlements extend the effective U.S. patent expiry for Vyndamax to June 1, 2031 (pending other... More
April 28, 2026 11:46 AM EDT
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $95.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "The PFE taf settlement date of June 2031 (w/ potential for 6 mos of exclusivity) gives BBIO 7.5-8 years to launch... More
April 28, 2026 11:25 AM EDT
Mizuho analyst Salim Syed reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "Pfizer (PFE, NC) just announced that the recent settlements with Dexcel, Cipla and Hikma (all NC) extended Vyndamax's LOE to 6/1/2031 (from YE2028).... More
April 28, 2026 9:48 AM EDT
Mizuho analyst Salim Syed reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "We've just learned that Hikma/PFE (both NC) settled in their current litigation of case 1:23-cv-00879 (Document 334), which follows both recent... More
